Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Open in API
Filings indexed 147 across all filing types
Latest filing 2025-12-19 Share Issue/Capital Cha…
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Zenas BioPharma, Inc. It registers shares of common stock to be issued pursuant to inducement stock option awards under the 2026 Inducement Plan. The document includes legal and regulatory disclosures typical of a securities registration statement, such as incorporation by reference of prior filings, indemnification provisions, and exhibits related to stock plans and agreements. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This type of filing is related to share issuance and capital changes rather than financial reporting, management changes, or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not merely an announcement or certification, so it is not RPA or RNS.
2025-12-19 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the adoption of a new inducement plan by the Board of Directors, including stock option agreements and restricted stock unit agreements. This relates to changes in compensatory arrangements and potentially appointments or departures of officers or directors. The key section is Item 5.02, which covers departure or election of directors or officers and compensatory arrangements. There is no financial data or earnings information, so it is not an earnings release or financial report. It is not a proxy statement or voting results announcement. The document is not a full annual or quarterly report. Therefore, the best classification is Board/Management Information (MANG), as it announces changes related to management compensation plans and inducements.
2025-12-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-15 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing its financial results for the quarter ended September 30, 2025. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive analysis itself. The length is 4079 characters, which is relatively short and consistent with a current report announcing earnings results rather than the full earnings release document. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). Since this is a Form 8-K announcing quarterly financial results with a press release, the best classification is Earnings Release (ER).
2025-11-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Zenas BioPharma, Inc. It is titled 'Current Report' and dated October 27, 2025. The content includes announcements of positive clinical trial results (Phase 2 MoonStone trial) and forward-looking statements about future trial data and development plans. There are no detailed financial statements or comprehensive financial analysis included. The document primarily serves as a regulatory disclosure of material events and updates rather than a full financial report or earnings release. It also includes a press release as an exhibit. Given the nature of the filing (Form 8-K) and the content focusing on clinical trial results and company updates, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.